TNF
11 articles
PharmacologyBritish Journal of Pharmacology
Prenatal vitamin D eases autism-like behaviours in mice, with sex-specific neuroimmune shifts
- A single vitamin D3 injection given to pregnant BTBR dams reduced repetitive, stereotyped behaviours in their offspring.
- In males, treatment lowered TNF-α protein in prefrontal cortex and hippocampus, and raised hippocampal FABP4 and TGF-β2 gene expression.
- TGF-β2 shifted in the opposite direction in females, suggesting sex-dependent neuroimmune responses in this preclinical model.
Without maternal and offspring serum 25-OH vitamin D, this can't be read as a vitamin D effect with any exposure logic; a single GD9 injection is a pharmacological bolus, not a repletion model. TNF-α and TGF-β2 shifts are biomarkers, not mechanism. Next step: dose-response, female behaviour, and a second ASD-relevant model beyond BTBR.
Computational & AIJournal of Computer-Aided Molecular Design (Springer Nature)
Random forest screen yields GSK-3β hit with cellular anti-inflammatory activity
- A random forest trained on literature GSK-3β inhibitors served as a first-pass filter for a commercial library, followed by ADMET filtering, docking and molecular dynamics.
- Two selected compounds showed only moderate enzymatic inhibition.
- The better one, a non-classical hindered aromatic ester, lowered TNF-α and IL-6 in cells with low cytotoxicity; the authors attribute this to lipophilicity and cellular accumulation, which was not directly tested.
Two tested compounds with only moderate enzyme inhibition is a modest return for a screen, and I'd want the denominator: how many random picks from the same filtered library would hit at that level? Without a docking-only or similarity-search baseline, the forest's contribution is unproven. Since the cell effect is unexplained, a counter-screen against other kinases would be my next step.
Paper: Journal of Computer-Aided Molecular Design (Springer Nature) ↗
PharmacologyBritish Journal of Pharmacology (Wiley)
Vitamin E directly blocks cIAP1 degradation and cell death signaling
- A screen found that vitamin E blocks TNF-α and SMAC mimetic-induced cell death through a mechanism separate from its antioxidant role.
- Binding assays indicate it competitively engages the BIR3 domain of cIAP1, preventing its degradation.
- Preserved cIAP1 limits formation of the RIPK1-dependent death complex, and treatment eased colitis severity in mice.
The colitis benefit is attributed to cIAP1 rather than redox, yet a lipophilic vitamin binding the BIR3 pocket needs a proper control to back that up. Non-antioxidant tocopherol analogs and cIAP1-knockout cells would test it. Also worth testing is whether vitamin E blunts SMAC mimetics in tumor models, the first clinically relevant consequence of this interaction.
PharmacologyACS Pharmacology & Translational Science
Sitagliptin in lipid nanoparticles calms neuroinflammation in mice, with NLCs ahead of SLNs
- Sitagliptin was packed into solid lipid nanoparticles and nanostructured lipid carriers of about 50 nm, optimised by experimental design.
- SLNs released drug more slowly; in HepG2 cells NLCs were better tolerated at higher concentrations.
- In a mouse neuroinflammation model both formulations improved behaviour and lowered brain TNF-α, with NLCs doing better.
The claim of enhanced brain delivery rests on a pharmacodynamic readout; without brain and plasma exposure of free versus encapsulated drug, and a Kp,uu, we cannot tell delivery from a formulation effect on dosing. A neuroinflammation model is also far from Alzheimer's pathology. I would want unbound brain exposure and a head-to-head against plain sitagliptin at the same dose.
Medicinal ChemistryOrganic Letters
Chromatography-free asymmetric route delivers over 20 g of a TNFα small molecule inhibitor with sharply higher overall yield
- A chromatography-free, enantioselective redesign of a lead TNFα small-molecule inhibitor's synthesis delivered over 20 g, with a large overall yield gain on the original route.
- A Parham cyclization quickly builds the key dihydroisoquinolone intermediate in large quantities.
- The route also opens uncommon asymmetric access to 4-hydroxy and 4-amino tetrahydroisoquinolines and reaches the heterocycle-rich pentacyclic core without copper.
Copper-free access to a crowded pentacyclic core is welcome, since trace metal can quietly distort biochemical readouts for trimer-disrupting chemotypes. Enantiopurity data are still missing, as is proof that the benzylic 4-stereocentre does not racemize under assay conditions. After that, the 4-hydroxy and 4-amino handles make a fast analogue sweep an obvious move.
PharmacologyScience Translational Medicine
Repurposed anticoagulant dabigatran hits BIG2 to curb TNF and IL-1 signaling in osteoarthritis
- A screen of approved drugs flagged dabigatran, a thrombin inhibitor, as a suppressor of both TNF-α and IL-1β signaling that restored chondrocyte metabolism.
- Pulldown with mass spectrometry identified BIG2 as its binding target; engagement promotes TNFR1 release and autophagy-lysosome degradation of IL-1R1.
- In mouse and cynomolgus macaque osteoarthritis models, treatment reduced cartilage degeneration and pain and improved joint function.
Dabigatran's day job is thrombin inhibition, so the decisive control is genetic: does BIG2 knockdown abolish the benefit, and does a thrombin-inactive analog keep it? Also unclear is whether cartilage exposure at a tolerable dose reaches in vitro concentrations. Chronic anticoagulant dosing for a non-lethal disease leaves little bleeding margin, so a BIG2-selective derivative is the sensible next step.
Medicinal ChemistryJournal of Medicinal Chemistry
Free-energy calculations and machine learning uncover diverse p38α–MK2 molecular glues
- Glue-type inhibitors that bridge p38α and MK2 act longer than classic active-site blockers, but the ternary-complex mechanism makes rational design hard.
- The team combined free energy perturbation with machine learning to rank compounds drawn from varied chemical sources in silico.
- This yielded several structurally distinct, potent, selective glues; two leads showed good exposure and cut TNFα in an LPS mouse model after oral dosing.
A team would next point this FEP-plus-ML triage at its own induced-proximity target, but first ask for the missing control: how did the ranking beat plain docking or a similarity screen on hit rate? For glues I'd also want cooperativity (ternary versus binary affinity) and residence time reported, since those, not potency alone, explain the durable effect.
PharmacologyScience Translational Medicine
TWEAK signaling linked to eczema-like reactions in psoriasis patients on biologics
- Some psoriasis patients treated with biologics against TNF, IL-17 or IL-23 develop eczema-like lesions resembling atopic dermatitis; the molecular drivers were unclear.
- Single-cell and spatial transcriptomic maps of patient skin showed expanded myeloid and T cell populations and keratinocytes shaped by TWEAK acting through its receptor TNFRSF12A.
- In cultured keratinocytes, TWEAK combined with IL-13 induced a type 2 and interferon-skewed epithelial program that partly reproduced the lesional signature.
Cultured keratinocytes plus recombinant cytokines show sufficiency at best, so I'd ask first whether TWEAK-high, TNFRSF12A-high skin predicts who flips to eczema before treatment. Then check drug exposure in skin, and whether blockade quiets the lesion without unmasking psoriasis again.
Medicinal ChemistryJournal of Medicinal Chemistry (ACS)
Structure-based design of pan-YTHDF m6A reader inhibitors with cellular activity in AML
- Structure-based design gave pan-YTHDF inhibitor 34, which spares the related YTHDC1 and YTHDC2 readers, backed by YTHDF2 co-crystal structures.
- Inhibitor 31 and its methylated inactive analogue 31b form a negative-control pair; thermal shift assays showed cellular target engagement for 34 and 31 but not 31b.
- Both actives slowed AML cell growth, and 31 raised TNFRSF1B transcript level and stability, sensitizing THP-1 cells to TNF-alpha toxicity.
An active and methylated-inactive pair is exactly what a chemical probe should come with, and it makes the TNFRSF1B story more believable. Still, pan-YTHDF inhibition cannot separate paralog roles. A YTHDF2 knockout or binding-site mutant rescue would show whether the AML growth effect is truly on-target.
PharmacologyBritish Journal of Pharmacology (Wiley)
TRPV3 turns out to be a driver of lung inflammation in mice
- TRPV3 expression rose in the lungs of mice with LPS- or carvacrol-induced acute lung injury, and activating the channel with carvacrol alone reproduced features of the injury.
- Genetic deletion or pharmacological inhibition of TRPV3 attenuated the lung injury.
- In alveolar epithelial cells, TRPV3 activation raised intracellular calcium, boosted cytokine and chemokine output and loosened tight junctions; TNF-α enhanced TRPV3 calcium responses, suggesting a feed-forward loop.
Knockout, inhibitor and agonist all pointing the same way is a decent validation package for an ion channel. The gap is that carvacrol isn't selective for TRPV3 (it hits TRPA1 too), and the inhibitors in this field have a patchy selectivity record, so the genetic arm carries the weight. TRPV3 antagonists are being pursued for skin, which makes lung safety and exposure an obvious next question.
Medicinal ChemistryJournal of Medicinal Chemistry (ACS)
Non-ATP-competitive MKK3 modulators suppress TNF-α in mouse colitis models
- ATP-competitive p38 inhibitors failed in the clinic partly through poor kinome selectivity, so the authors targeted the upstream kinase MKK3 through a non-ATP-competitive pocket.
- The lead, (R)-48, suppressed TNF-α production, was highly orally bioavailable and showed dose-dependent efficacy with clear PK/PD relationships in mouse ulcerative colitis models.
- Biophysical data (HDX-MS) were used to probe how the compounds engage MKK3.
Moving one node upstream of p38 is a sensible way around the selectivity problem that sank the first-generation inhibitors. An oral, TNF-lowering small molecule for UC would be a genuinely different option next to injectable biologics. My concern is the allosteric pocket: SAR for non-ATP-site kinase binders can be steep and hard to translate between species, so I'd check the human-protein data early.